On January 29th, 2013, Genzyme (a Sanofi company), and Isis Pharmaceuticals Inc. announced that after two years of patient clinical trials the US Food and Drug Administration has approved Kynamro ™ (generic name: mipomersen sodium) for the treatment of Homozygous Familial Hypercholesterolemia, the … Read More
On January 29th, 2013 …. announced that the FDA approved a new HoFH drug, KYNAMRO (mepomersen). Within only two months, two drugs have become available for those affected by Homozygous Familial Hypercholesterolemia. We will be updating you with more news about this exciting development as it breaks. … Read More
There is no cure for homozygous familial hypercholesterolemia, the most severe form of FH. This extremely rare form of the disease occurs in less than one in a million people, and when an individual has it, they often go through a period of time where they try a number of different treatments before … Read More
Carl Oullette had his first heart attack at 34. Or so he thought initially.After taking a closer look at his medical history, Carl thinks he may have had a series of heart attacks, which went unrecognized. Symptoms included sudden paleness, breaking into sweat, chest pains and numbness in his arms.When … Read More
The FH Foundation recently celebrated their first anniversary. Dedicated to raising awareness of this genetic condition and available treatments, the Foundation shares some of its accomplishments.The FH Foundation recently celebrated their first anniversary. Dedicated to raising awareness of this genetic … Read More
Because familial hypercholesterolemia can be passed on to children if either or both parents have the same disorder, it should be easy to identify this dangerous genetic disease in patients with high cholesterol or heart problems. If both parents have FH there is a 75% likelihood that each of their … Read More
Dedicated to advocating for individuals with hereditary cardiovascular disorder, Familial Hypercholesterolemia, the FH Foundation proudly welcomes three new board members: Ted Tussing, Josh Knowles, MD, PhD, and Vaughn Davis.Online PR News – 03-January-2013 –It’s a disease that 80% of the … Read More
On Dec 24th, 2012 Aegerion Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) approved new treatment for Homozygous Familial Hypercholesterolemia (HoFH) called JUXTAPID™ (lomitapide). The capsules are intended as an adjunct to a low-fat diet and other cholesterol-lowering … Read More
Doctors’ failures caused our daughter’s deathA schoolgirl was not given a simple blood test despite warning signs that she had dangerous cholesterol levels – and thousands more adults and children are at risk. Jane Feinmann reports . John and Amanda Wingett at home. Their daughter … Read More
In September, the FH Foundation participated in the “New Strategies in Public Health Genomics” conference at the Centers for Disease Control (CDC). Experts and key stakeholders, including advocates, community leaders and clinicians, came together to discuss evidence-based genomic programs … Read More
